FDA's New Guidelines Benefit PM; ZYN Ultra Expected to Launch Quickly

Overview

This report reiterates a 'Buy' rating on Philip Morris International (PM). The core thesis centers on the U.S. Food and Drug Administration (FDA) issuing new industry guidance clarifying that it will not prioritize enforcement against nicotine pouch products—such as ZYN Ultra—that have submitted robust Premarket Tobacco Product Applications (PMTAs). Goldman Sachs believes this clears regulatory hurdles, allowing PM to swiftly launch ZYN Ultra, with retail availability expected within months. This development is viewed as a critical positive catalyst for the stock, helping accelerate ZYN brand growth and improving near-term earnings expectations.

Core views

Significantly improved regulatory environment: The FDA’s new guidance provides a clearer regulatory pathway for innovation in nicotine pouches and e-vapor products. The guidance states that for products with submitted PMTAs, regulators will publish a public list of those meeting specific criteria and thus not subject to prioritized enforcement. This not only facilitates the rapid launch of ZYN Ultra but also supports other upcoming ZYN innovations planned by PM in the coming months, such as low-nicotine ZYN X-Low and third-generation ZYN products. Product competitiveness and channel feedback: ZYN Ultra is a moist nicotine pouch offering higher nicotine content (9mg+) and more flavor options compared to existing dry-format ZYN products (3–6mg nicotine). Industry contacts believe ZYN Ultra delivers a slightly superior user experience relative to its main competitor, VELO Plus. Channel surveys indicate growing retailer confidence in the ZYN brand—approximately 80% of surveyed retailers plan to allocate more shelf space to ZYN this year, up significantly from 69% last quarter, with some already reserving space ahead of ZYN Ultra’s launch. Valuation and growth outlook: PM is transforming into a faster-growing, higher-margin business. Despite revenue and EPS growth far outpacing peers, its valuation still trades at roughly a 17% discount to the average of high-growth consumer staples peers. Goldman Sachs expects PM to sustain strong top- and bottom-line growth in the coming years, driven by the compounding effects of IQOS and opportunities within the ZYN portfolio.

Analysis framework

Goldman Sachs’ analysis follows the framework of 'Regulatory Catalyst → Product Launch → Channel Validation → Valuation Re-rating.' First, it interprets the FDA’s latest policy guidance to conclude that reduced regulatory risk is the most significant near-term variable. Second, it combines the company’s product pipeline and management commentary to project ZYN Ultra’s launch timeline and competitive advantages. Third, it cites independent retailer survey data (Nicotine Nuggets Q1 survey) to validate channel acceptance and inventory readiness. Finally, it compares PM’s valuation multiples against other high-growth consumer staples companies to argue that the current share price is undervalued, thereby supporting the Buy rating.

Methodology notes

• Event Arbitrage and Behavioral FinanceEvent-driven analysis

  Regulatory policy change as an event-driven factor

  The report treats the FDA’s issuance of new guidance as a clear external event, analyzing how it removes market uncertainty and directly triggers the company’s product launch process, thereby impacting the stock price—an archetypal event-driven analytical logic.

• Industry/ Sector Analysis FrameworkSupply-demand framework

  Retailer inventory and shelf-space allocation

  By analyzing retailers’ willingness to allocate shelf space (a demand-side signal), the report forecasts post-launch sales potential—a common channel-tracking method in consumer goods analysis.

• Valuation MethodologyPE/PEG valuation

  Relative valuation and growth premium

  The report compares PM’s P/E ratio against its growth rate and those of other high-growth consumer staples peers, highlighting a valuation discount that implicitly incorporates PEG (Price/Earnings to Growth) logic.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Philip Morris International (PM.US)

  Direct beneficiary; owner of the ZYN brand; FDA’s new rules directly remove its product launch barriers

  Strengths

  Strong brand equity, robust innovation pipeline (ZYN Ultra, X-Low, etc.), dual growth engines from IQOS and ZYN

  Weaknesses

  Previously lagged competitors in nicotine pouches due to product specification constraints

  Comparison

  ZYN Ultra is perceived as slightly superior to competitors like VELO Plus in user experience and nicotine delivery technology

  Risks

  Execution risk, potential re-tightening of regulations, global economic recession impacting premium consumer demand

Key data

• 12-Month Target Price$205Based on 21.5x P/E and 16.2x EV/EBITDA multiples
• Current Share Price$170.99As of May 8, 2026, closing price
• Upside Potential19.9%Calculated based on target price vs. current price
• Retailers Increasing Shelf Space Allocation~80%Q1 survey data, up from ~69% in Q4
• ZYN Ultra Nicotine Content9mg+Higher than existing dry-format ZYN products (3–6mg)
• Valuation Discount~17%Relative to average valuation of high-growth consumer staples peers

Impact & implications

For PM, the swift launch of ZYN Ultra will address its previous competitive disadvantage in the nicotine pouch category due to limited flavor and nicotine strength offerings, potentially reigniting ZYN brand growth momentum. For the broader industry, the FDA’s guidance signals a shift in regulatory stance—from pure restriction toward acceptance of compliant innovative products—supporting the long-term development of nicotine pouches and e-vapor categories. Investors should note PM as one of the few high-growth names in consumer staples, with meaningful valuation re-rating potential.

Risks

• Execution risk: PM could fall behind if competitors introduce superior technologies
• Regulatory and legislative risk: Stricter tobacco sales regulations or equal taxation of reduced-risk products with combustible cigarettes would severely impact profitability
• Global recession: Economic downturn or heightened inflation could weaken consumer purchasing power, affecting demand for premium cigarettes and IQOS

What to watch

• Actual retail shelf placement timing of ZYN Ultra
• FDA’s public list of products meeting non-prioritized enforcement criteria
• Rollout progress of subsequent ZYN innovations (e.g., ZYN X-Low) in the U.S.